Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Upstream Bio plans to initiate pivotal Phase 3 trials in Q1 2027 for verekitug, a novel TSLP receptor antagonist, in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The trials will evaluate a 400 mg dose administered every 12 weeks versus placebo, targeting broad patient populations. Successful Phase 3 results could lead to FDA…